Related Experiment Video
Updated: Aug 4, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
Chikungunya virus infections: time to act, time to treat
Rana Abdelnabi1, Johan Neyts1, Leen Delang1
1University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Abstract:
Chikungunya virus (CHIKV) is a re-emerging alphavirus that caused massive outbreaks of Chikungunya fever in several countries and regions in Africa, Asia and more recently in Central and South America. An acute CHIKV infection is usually associated with fever and arthritis and it is rarely fatal. However, 15-60% of patients suffer from chronic polyarthralgia for weeks, months or even for several years after the acute infection. There are currently no vaccines or antivirals available for the prevention or treatment of CHIKV infections. The development of potent and safe antivirals for prophylaxis (e.g., during travel to CHIKV-endemic regions) and treatment of CHIKV infections is urgently needed. We here review some of the recently reported CHIKV inhibitors, both directly-acting and host-targeting compounds.
Related Concept Videos
Rocky Mountain Spotted Fever
Arboviral Encephalitis
Yellow Fever
Malaria
American Trypanosomiasis
Trichomoniasis

